{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T10:53:06Z","timestamp":1789901586953,"version":"4.0.1"},"reference-count":84,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2012,6,1]],"date-time":"2012-06-01T00:00:00Z","timestamp":1338508800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2012,6,1]],"date-time":"2012-06-01T00:00:00Z","timestamp":1338508800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaad.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American Academy of Dermatology"],"published-print":{"date-parts":[[2012,6]]},"DOI":"10.1016\/j.jaad.2011.09.029","type":"journal-article","created":{"date-parts":[[2011,12,11]],"date-time":"2011-12-11T10:30:57Z","timestamp":1323599457000},"page":"995-1003","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":139,"title":["Toxic epidermal necrolysis: Review of pathogenesis and management"],"prefix":"10.1016","volume":"66","author":[{"given":"Andrew","family":"Downey","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chris","family":"Jackson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadia","family":"Harun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan","family":"Cooper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaad.2011.09.029_bib1","doi-asserted-by":"crossref","first-page":"9","DOI":"10.2332\/allergolint.55.9","article-title":"Toxic epidermal necrolysis and Stevens Johnson syndrome: our current understanding","volume":"55","author":"French","year":"2006","journal-title":"Allergol Int"},{"key":"10.1016\/j.jaad.2011.09.029_bib2","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.jaad.2006.04.048","article-title":"Toxic epidermal necrolysis","volume":"56","author":"Pereira","year":"2007","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2011.09.029_bib3","series-title":"Fitzpatrick\u2019s Dermatology in general medicine","author":"Wolff","year":"2007"},{"key":"10.1016\/j.jaad.2011.09.029_bib4","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1001\/archderm.1993.01680290135026","article-title":"Incidence of Stevens-Johnson syndrome and toxic epidermal necrolysis in patients with the acquired immunodeficiency syndrome in Germany","volume":"129","author":"Rzany","year":"1993","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jaad.2011.09.029_bib5","doi-asserted-by":"crossref","first-page":"132","DOI":"10.4049\/jimmunol.170.1.132","article-title":"A novel polymorphic CAAT\/enhancer-binding protein beta element in the FasL gene promoter alters Fas ligand expression: a candidate background gene in African American systemic lupus erythematosus patients","volume":"170","author":"Wu","year":"2003","journal-title":"J Immunol"},{"key":"10.1016\/j.jaad.2011.09.029_bib6","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1001\/archderm.141.6.683","article-title":"Uncovering histologic criteria with prognostic significance in toxic epidermal necrolysis","volume":"141","author":"Quinn","year":"2005","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jaad.2011.09.029_bib7","first-page":"3","article-title":"Toxic epidermal necrolysis: revisiting the tentative link between early apoptosis and late necrosis (review)","volume":"19","author":"Paquet","year":"2007","journal-title":"Int J Mol Med"},{"key":"10.1016\/j.jaad.2011.09.029_bib8","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1056\/NEJM199411103311906","article-title":"Severe adverse cutaneous reactions to drugs","volume":"331","author":"Roujeau","year":"1994","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaad.2011.09.029_bib9","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/S1081-1206(10)61112-X","article-title":"Stevens-Johnson syndrome and toxic epidermal necrolysis: a review of the literature","volume":"94","author":"Letkko","year":"2005","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.jaad.2011.09.029_bib10","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1097\/01.BCR.0000216532.71360.9B","article-title":"SCORTEN overestimates mortality in the setting of a standardized treatment protocol","volume":"27","author":"Imahara","year":"2006","journal-title":"J Burn Care Res"},{"key":"10.1016\/j.jaad.2011.09.029_bib11","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1136\/pgmj.2007.061465","article-title":"Management of toxic epidermal necrolysis and related syndromes","volume":"84","author":"Mukasa","year":"2008","journal-title":"Postgrad Med J"},{"key":"10.1016\/j.jaad.2011.09.029_bib12","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1046\/j.1523-1747.2000.00061.x","article-title":"SCORTEN: a severity-of-illness score for toxic epidermal necrolysis","volume":"115","author":"Bastuji-Garin","year":"2000","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jaad.2011.09.029_bib13","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1038\/sj.jid.5701033","article-title":"Stevens-Johnson syndrome and toxic epidermal necrolysis: assessment of medication risks with emphasis on recently marketed drugs. The EuroSCAR study","volume":"128","author":"Mockenhaupt","year":"2008","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jaad.2011.09.029_bib14","first-page":"59","article-title":"Toxic epidermal necrolysis following morbilli-parotitis vaccination","volume":"13","author":"Dobrosavljevic","year":"1999","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.jaad.2011.09.029_bib15","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1136\/adc.53.1.38","article-title":"Mycoplasma pneumoniae infections in children","volume":"53","author":"Stevens","year":"1978","journal-title":"Arch Dis Child"},{"key":"10.1016\/j.jaad.2011.09.029_bib16","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1038\/428486a","article-title":"Medical genetics: a marker for Stevens-Johnson syndrome","volume":"428","author":"Chung","year":"2004","journal-title":"Nature"},{"key":"10.1016\/j.jaad.2011.09.029_bib17","doi-asserted-by":"crossref","first-page":"4134","DOI":"10.1073\/pnas.0409500102","article-title":"HLA-B\u22175801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol","volume":"102","author":"Hung","year":"2005","journal-title":"Proc Natl Acad Sci U\u00a0S\u00a0A"},{"key":"10.1016\/j.jaad.2011.09.029_bib18","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.1111\/j.1528-1167.2008.01719.x","article-title":"Carbamazepine and phenytoin induced Stevens-Johnson syndrome is associated with HLA-B\u22171502 allele in Thai population","volume":"49","author":"Locharernkul","year":"2008","journal-title":"Epilepsia"},{"key":"10.1016\/j.jaad.2011.09.029_bib19","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1111\/j.1528-1167.2007.01022.x","article-title":"Association between HLA-B\u22171502 allele and antiepileptic drug-induced cutaneous reactions in Han Chinese","volume":"48","author":"Man","year":"2007","journal-title":"Epilepsia"},{"key":"10.1016\/j.jaad.2011.09.029_bib20","unstructured":"Information for Healthcare Professionals: Dangerous or Even Fatal Skin Reactions - Carbamazepine. United States Food and Drug Administration. Available from: http:\/\/www.fda.gov\/Drugs\/DrugSafety\/PostmarketDrugSafetyInformationforPatientsandProviders\/ucm124718.htm. Accessed November 16, 2011."},{"key":"10.1016\/j.jaad.2011.09.029_bib21","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.jaci.2006.03.005","article-title":"Activation of T cells by carbamazepine and carbamazepine metabolites","volume":"118","author":"Wu","year":"2006","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaad.2011.09.029_bib22","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.2217\/14622416.9.11.1617","article-title":"HLA-B locus in Japanese patients with anti-epileptics and allopurinol-related Stevens-Johnson syndrome and toxic epidermal necrolysis","volume":"9","author":"Kaniwa","year":"2008","journal-title":"Pharmacogenomics"},{"key":"10.1016\/j.jaad.2011.09.029_bib23","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1097\/FPC.0b013e3282f3ef9c","article-title":"A European study of HLA-B in Stevens-Johnson syndrome and toxic epidermal necrolysis related to five high-risk drugs","volume":"18","author":"Lonjou","year":"2008","journal-title":"Pharmacogenet Genomics"},{"key":"10.1016\/j.jaad.2011.09.029_bib24","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1097\/FPC.0b013e328330a3b8","article-title":"Strong association between HLA-B\u22175801 and allopurinol-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in a Thai population","volume":"19","author":"Tassaneeyakul","year":"2009","journal-title":"Pharmacogenet Genomics"},{"key":"10.1016\/j.jaad.2011.09.029_bib25","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.jdermsci.2008.06.003","article-title":"Toxic epidermal necrolysis and Stevens-Johnson syndrome: soluble Fas ligand involvement in the pathomechanisms of these diseases","volume":"52","author":"Abe","year":"2008","journal-title":"J Dermatol Sci"},{"key":"10.1016\/j.jaad.2011.09.029_bib26","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1126\/science.282.5388.490","article-title":"Inhibition of toxic epidermal necrolysis by blockade of CD95 with human intravenous immunoglobulin","volume":"282","author":"Viard","year":"1998","journal-title":"Science"},{"key":"10.1016\/j.jaad.2011.09.029_bib27","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1016\/S0002-9440(10)64284-8","article-title":"Toxic epidermal necrolysis and Stevens-Johnson syndrome are induced by soluble Fas ligand","volume":"162","author":"Abe","year":"2003","journal-title":"Am J Pathol"},{"key":"10.1016\/j.jaad.2011.09.029_bib28","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1038\/sj.jid.5700648","article-title":"Soluble FAS ligand: a discriminating feature between drug-induced skin eruptions and viral exanthemas","volume":"127","author":"Stur","year":"2007","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jaad.2011.09.029_bib29","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1016\/j.jaci.2009.01.064","article-title":"The influence of hepatic damage on serum soluble Fas ligand levels of patients with drug rashes","volume":"123","author":"Tohyama","year":"2009","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaad.2011.09.029_bib30","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1111\/j.1365-2133.2008.08750.x","article-title":"A marked increase in serum soluble Fas ligand in drug-induced hypersensitivity syndrome","volume":"159","author":"Tohyama","year":"2008","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2011.09.029_bib31","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1038\/nm.1884","article-title":"Granulysin is a key mediator for disseminated keratinocyte death in Stevens-Johnson syndrome and toxic epidermal necrolysis","volume":"14","author":"Chung","year":"2008","journal-title":"Nat Med"},{"key":"10.1016\/j.jaad.2011.09.029_bib32","doi-asserted-by":"crossref","first-page":"5243","DOI":"10.4049\/jimmunol.174.9.5243","article-title":"Granulysin, a cytolytic molecule, is also a chemoattractant and proinflammatory activator","volume":"174","author":"Deng","year":"2005","journal-title":"J Immunol"},{"key":"10.1016\/j.jaad.2011.09.029_bib33","doi-asserted-by":"crossref","first-page":"189","DOI":"10.2165\/11532540-000000000-00000","article-title":"New insights in toxic epidermal necrolysis (Lyell\u2019s syndrome): clinical considerations, pathobiology and targeted treatments revisited","volume":"33","author":"Paquet","year":"2010","journal-title":"Drug Saf"},{"key":"10.1016\/j.jaad.2011.09.029_bib34","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1159\/000097652","article-title":"Glutathione-S-transferase pi expression in toxic epidermal necrolysis: a marker of putative oxidative stress in keratinocytes","volume":"20","author":"Paquet","year":"2007","journal-title":"Skin Pharmacol Physiol"},{"key":"10.1016\/j.jaad.2011.09.029_bib35","doi-asserted-by":"crossref","first-page":"445","DOI":"10.3109\/10409239509083491","article-title":"The glutathione S-transferase supergene family: regulation of GST and the contribution of the isoenzymes to cancer chemoprotection and drug resistance","volume":"30","author":"Hayes","year":"1995","journal-title":"Crit Rev Biochem Mol Biol"},{"key":"10.1016\/j.jaad.2011.09.029_bib36","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1007\/s001050050502","article-title":"[Plasmapheresis and immunopathogenetic aspects of toxic epidermal necrolysis]","volume":"47","author":"Hermes","year":"1996","journal-title":"Hautarzt"},{"key":"10.1016\/j.jaad.2011.09.029_bib37","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1001\/archderm.1994.01690050073012","article-title":"Macrophages and tumor necrosis factor alpha in toxic epidermal necrolysis","volume":"130","author":"Paquet","year":"1994","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jaad.2011.09.029_bib38","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1067\/mai.2002.120563","article-title":"Delayed reactions to drugs show levels of perforin, granzyme B, and Fas-L to be related to disease severity","volume":"109","author":"Posadas","year":"2002","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaad.2011.09.029_bib39","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1006\/bcmd.2002.0555","article-title":"Gene expression levels of cytokine profile and cytotoxic markers in non-immediate reactions to drugs","volume":"29","author":"Posadas","year":"2002","journal-title":"Blood Cells Mol Dis"},{"key":"10.1016\/j.jaad.2011.09.029_bib40","doi-asserted-by":"crossref","first-page":"7140","DOI":"10.4049\/jimmunol.162.12.7140","article-title":"Crosstalk between keratinocytes and T lymphocytes via Fas\/Fas ligand interaction: modulation by cytokines","volume":"162","author":"Arnold","year":"1999","journal-title":"J Immunol"},{"key":"10.1016\/j.jaad.2011.09.029_bib41","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1111\/j.1365-2133.2005.06721.x","article-title":"Toxic epidermal necrolysis: current evidence, practical management and future directions","volume":"153","author":"Chave","year":"2005","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2011.09.029_bib42","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/S0031-6997(25)06663-3","article-title":"Nitric oxide: physiology, pathophysiology, and pharmacology","volume":"43","author":"Moncada","year":"1991","journal-title":"Pharmacol Rev"},{"key":"10.1016\/j.jaad.2011.09.029_bib43","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1006\/niox.1997.0118","article-title":"Nitric oxide: cytotoxicity versus cytoprotection\u2014how, why, when, and where?","volume":"1","author":"Kroncke","year":"1997","journal-title":"Nitric Oxide"},{"key":"10.1016\/j.jaad.2011.09.029_bib44","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1016\/j.jaci.2009.10.030","article-title":"CD94\/NKG2C is a killer effector molecule in patients with Stevens-Johnson syndrome and toxic epidermal necrolysis","volume":"125","author":"Morel","year":"2010","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaad.2011.09.029_bib45","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1016\/j.jaci.2004.07.047","article-title":"Toxic epidermal necrolysis: effector cells are drug-specific cytotoxic T cells","volume":"114","author":"Nassif","year":"2004","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaad.2011.09.029_bib46","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1111\/j.1365-2133.2008.08516.x","article-title":"In\u00a0vivo dynamics of intraepidermal CD8+ T cells and CD4+ T cells during the evolution of fixed drug eruption","volume":"158","author":"Mizukawa","year":"2008","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2011.09.029_bib47","doi-asserted-by":"crossref","first-page":"8071","DOI":"10.4049\/jimmunol.0804002","article-title":"Defective regulatory T cells in patients with severe drug eruptions: timing of the dysfunction is associated with the pathological phenotype and outcome","volume":"182","author":"Takahashi","year":"2009","journal-title":"J Immunol"},{"key":"10.1016\/j.jaad.2011.09.029_bib48","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1111\/j.1365-2133.2009.09627.x","article-title":"Differential gene expression in drug hypersensitivity reactions: induction of alarmins in severe bullous diseases","volume":"162","author":"Bellon","year":"2010","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2011.09.029_bib49","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1111\/j.1600-0625.2010.01176.x","article-title":"Death ligand TRAIL, secreted by CD1a+ and CD14+ cells in blister fluids, is involved in killing keratinocytes in toxic epidermal necrolysis","volume":"20","author":"de Araujo","year":"2011","journal-title":"Exp Dermatol"},{"key":"10.1016\/j.jaad.2011.09.029_bib50","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1111\/j.1365-2133.2009.09357.x","article-title":"Endothelial cell apoptosis in severe drug-induced bullous eruptions","volume":"161","author":"Verneuil","year":"2009","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2011.09.029_bib51","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1001\/archderm.136.3.323","article-title":"Toxic epidermal necrolysis and Stevens-Johnson syndrome: does early withdrawal of causative drugs decrease the risk of death?","volume":"136","author":"Garcia-Doval","year":"2000","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jaad.2011.09.029_bib52","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1097\/00006534-199809020-00014","article-title":"Toxic epidermal necrolysis syndrome: mortality rate reduced with early referral to regional burn center","volume":"102","author":"McGee","year":"1998","journal-title":"Plast Reconstr Surg"},{"key":"10.1016\/j.jaad.2011.09.029_bib53","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1097\/00004630-200203000-00004","article-title":"A multicenter review of toxic epidermal necrolysis treated in U.S. burn centers at the end of the twentieth century","volume":"23","author":"Palmieri","year":"2002","journal-title":"J Burn Care Rehabil"},{"key":"10.1016\/j.jaad.2011.09.029_bib54","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1097\/BCR.0b013e3181848bb1","article-title":"Toxic epidermal necrolysis clinical guidelines","volume":"29","author":"Endorf","year":"2008","journal-title":"J Burn Care Res"},{"key":"10.1016\/j.jaad.2011.09.029_bib55","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/j.burns.2007.06.008","article-title":"Toxic epidermal necrolysis: use of Biobrane or skin coverage reduces pain, improves mobilisation and decreases infection in elderly patients","volume":"34","author":"Boorboor","year":"2008","journal-title":"Burns"},{"key":"10.1016\/j.jaad.2011.09.029_bib56","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1097\/PRS.0b013e3181773d5d","article-title":"Antishear therapy for toxic epidermal necrolysis: an alternative treatment approach","volume":"122","author":"Dorafshar","year":"2008","journal-title":"Plast Reconstr Surg"},{"key":"10.1016\/j.jaad.2011.09.029_bib57","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.burns.2006.12.008","article-title":"AQUACEL Ag in the treatment of toxic epidermal necrolysis (TEN)","volume":"34","author":"Huang","year":"2008","journal-title":"Burns"},{"key":"10.1016\/j.jaad.2011.09.029_bib58","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1001\/archderm.1987.01660330071012","article-title":"Toxic epidermal necrolysis. Clinical findings and prognosis factors in 87 patients","volume":"123","author":"Revuz","year":"1987","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jaad.2011.09.029_bib59","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1097\/00000658-198611000-00001","article-title":"Improved burn center survival of patients with toxic epidermal necrolysis managed without corticosteroids","volume":"204","author":"Halebian","year":"1986","journal-title":"Ann Surg"},{"key":"10.1016\/j.jaad.2011.09.029_bib60","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.1001\/jama.1987.03390160057026","article-title":"Toxic epidermal necrolysis. A step forward in treatment","volume":"257","author":"Heimbach","year":"1987","journal-title":"JAMA"},{"key":"10.1016\/j.jaad.2011.09.029_bib61","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.jaad.2007.08.039","article-title":"Effects of treatments on the mortality of Stevens-Johnson syndrome and toxic epidermal necrolysis: a retrospective study on patients included in the prospective EuroSCAR Study","volume":"58","author":"Schneck","year":"2008","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2011.09.029_bib62","first-page":"340","article-title":"Toxic epidermal necrolysis: a systemic and dermatologic disorder best treated with standard treatment protocols in burn intensive care units without the prolonged use of corticosteroids","volume":"180","author":"Herndon","year":"1995","journal-title":"J Am Coll Surg"},{"key":"10.1016\/j.jaad.2011.09.029_bib63","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1111\/j.1365-4632.2004.02048.x","article-title":"Prospective, noncomparative open study from Kuwait of the role of intravenous immunoglobulin in the treatment of toxic epidermal necrolysis","volume":"43","author":"Al-Mutairi","year":"2004","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.jaad.2011.09.029_bib64","first-page":"430","article-title":"High-dose intravenous immunoglobulin for severe drug reactions: efficacy in toxic epidermal necrolysis","volume":"83","author":"Campione","year":"2003","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.jaad.2011.09.029_bib65","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1159\/000070957","article-title":"Effect of high-dose intravenous immunoglobulin therapy in Stevens-Johnson syndrome: a retrospective, multicenter study","volume":"207","author":"Prins","year":"2003","journal-title":"Dermatology"},{"key":"10.1016\/j.jaad.2011.09.029_bib66","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1097\/01.BCR.0000124746.33279.86","article-title":"Intravenous immunoglobulin does not improve outcome in toxic epidermal necrolysis","volume":"25","author":"Shortt","year":"2004","journal-title":"J Burn Care Rehabil"},{"key":"10.1016\/j.jaad.2011.09.029_bib67","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1159\/000051702","article-title":"Toxic epidermal necrolysis treated with intravenous high-dose immunoglobulins: our experience","volume":"203","author":"Stella","year":"2001","journal-title":"Dermatology"},{"key":"10.1016\/j.jaad.2011.09.029_bib68","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1001\/archderm.139.1.39","article-title":"Analysis of intravenous immunoglobulin for the treatment of toxic epidermal necrolysis using SCORTEN: The University of Miami Experience","volume":"139","author":"Trent","year":"2003","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jaad.2011.09.029_bib69","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1067\/mjd.2002.127249","article-title":"Treatment of toxic epidermal necrolysis with intravenous immunoglobulin in children","volume":"47","author":"Tristani-Firouzi","year":"2002","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2011.09.029_bib70","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1097\/01.BCR.0000105096.93526.27","article-title":"Toxic epidermal necrolysis: does immunoglobulin make a difference?","volume":"25","author":"Brown","year":"2004","journal-title":"J Burn Care Rehabil"},{"key":"10.1016\/j.jaad.2011.09.029_bib71","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1001\/archderm.139.1.33","article-title":"Intravenous immunoglobulin treatment for Stevens-Johnson syndrome and toxic epidermal necrolysis: a prospective noncomparative study showing no benefit on mortality or progression","volume":"139","author":"Bachot","year":"2003","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jaad.2011.09.029_bib72","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/j.intimp.2005.11.012","article-title":"Use of intravenous immunoglobulin in toxic epidermal necrolysis and Stevens-Johnson syndrome: our current understanding","volume":"6","author":"French","year":"2006","journal-title":"Int Immunopharmacol"},{"key":"10.1016\/j.jaad.2011.09.029_bib73","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.sder.2006.04.004","article-title":"Toxic epidermal necrolysis and intravenous immunoglobulin: a review","volume":"25","author":"Trent","year":"2006","journal-title":"Semin Cutan Med Surg"},{"key":"10.1016\/j.jaad.2011.09.029_bib74","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1046\/j.1526-0968.2002.00409.x","article-title":"Plasma exchange in patients with toxic epidermal necrolysis","volume":"6","author":"Bamichas","year":"2002","journal-title":"Ther Apher"},{"key":"10.1016\/j.jaad.2011.09.029_bib75","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1046\/j.1365-4362.1997.00192.x","article-title":"Plasmapheresis in toxic epidermal necrolysis","volume":"36","author":"Chaidemenos","year":"1997","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.jaad.2011.09.029_bib76","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1016\/S0190-9622(99)70497-4","article-title":"Plasmapheresis as an adjunct treatment in toxic epidermal necrolysis","volume":"40","author":"Egan","year":"1999","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2011.09.029_bib77","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1001\/archderm.1985.01660120074023","article-title":"Plasmapheresis in severe drug-induced toxic epidermal necrolysis","volume":"121","author":"Kamanabroo","year":"1985","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jaad.2011.09.029_bib78","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1177\/039139889101401006","article-title":"Plasma exchange (PE) treatment in drug-induced toxic epidermal necrolysis (TEN)","volume":"14","author":"Sakellariou","year":"1991","journal-title":"Int J Artif Organs"},{"key":"10.1016\/j.jaad.2011.09.029_bib79","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1097\/00005373-200003000-00017","article-title":"Treatment of toxic epidermal necrolysis with cyclosporin A","volume":"48","author":"Arevalo","year":"2000","journal-title":"J Trauma"},{"key":"10.1016\/j.jaad.2011.09.029_bib80","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1046\/j.1365-2133.2002.46833.x","article-title":"Antitumour necrosis factor-alpha antibodies (infliximab) in the treatment of a patient with toxic epidermal necrolysis","volume":"146","author":"Fischer","year":"2002","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2011.09.029_bib81","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1097\/00007611-199610000-00015","article-title":"Cyclophosphamide in the treatment of toxic epidermal necrolysis","volume":"89","author":"Frangogiannis","year":"1996","journal-title":"South Med J"},{"key":"10.1016\/j.jaad.2011.09.029_bib82","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1016\/S0140-6736(98)02197-7","article-title":"Randomised comparison of thalidomide versus\u00a0placebo in toxic epidermal necrolysis","volume":"352","author":"Wolkenstein","year":"1998","journal-title":"Lancet"},{"key":"10.1016\/j.jaad.2011.09.029_bib83","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1111\/j.1365-2133.1997.tb02175.x","article-title":"Drug-induced hypersensitivity syndrome and toxic epidermal necrolysis. Treatment with N-acetylcysteine","volume":"136","author":"Redondo","year":"1997","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2011.09.029_bib84","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1067\/mjd.2002.118557","article-title":"Toxic epidermal necrolysis treated with N-acetylcysteine","volume":"46","author":"Velez","year":"2002","journal-title":"J Am Acad Dermatol"}],"container-title":["Journal of the American Academy of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962211010772?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962211010772?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T22:24:12Z","timestamp":1759271052000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0190962211010772"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,6]]},"references-count":84,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2012,6]]}},"alternative-id":["S0190962211010772"],"URL":"https:\/\/doi.org\/10.1016\/j.jaad.2011.09.029","relation":{},"ISSN":["0190-9622"],"issn-type":[{"value":"0190-9622","type":"print"}],"subject":[],"published":{"date-parts":[[2012,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Toxic epidermal necrolysis: Review of pathogenesis and management","name":"articletitle","label":"Article Title"},{"value":"Journal of the American Academy of Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaad.2011.09.029","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2011 American Academy of Dermatology, Inc. Published by Mosby, Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}